0 CHECKOUT

Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

  • ID: 3308672
  • July 2015
  • Region: China
  • 182 pages
  • Kelly Scientific Publications
1 of 5
As the Current Second Market Leader its Predicted that the Chinese Pharma Market will be the Main Competitor of the US By 2020

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • MORE

“Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challengess” provides a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages.

The Chinese biopharmaceutical market is presented as follows:
- By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
- By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:
- Company financials, sales & revenue figures
- China GDP, economic growth, export (bulk drug, formulations) figures
- Indian health expenditure as a function of GDP
- Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
- Economic growth figures of advanced economies (USA, UK, Germany, READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • MORE

1.0 Summary

1.1 Objectives of Report

1.2 Scope of Study

1.3 Data Sources and Methodology

1.4 Key Findings and Observations

1.5 Executive Summary

1.5.1 Chronic Disease in China

1.5.2 Chinese Pharmaceutical Market

1.5.3 Government and Regulation Environment 12th Five Year Plan

1.5.4 Generic Medication Market and China

1.5.5 Novel Product Drug development

1.5.6 Global Pharmaceutical Companies Interest in China

2.0 Chronic Disease Prevalence Statistics

3.0 Business Environment

3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics

3.2 Gross Domestic Product of China Analysis

3.3 Annual Health Expenditure in China Analysis

3.4 Global and Chinese Economic History

3.5 Chinese Economic History in Comparison to Emerging Markets and Developing Countries

3.6 Chinese Economic History in Comparison to Advanced Economies (US, Europe)

4.0 Chinese Pharmaceutical Market

4.1 Global Pharma Market Overview

4.2 China Pharma Market Overview

4.3 Main Players in China’s Pharmaceutical Industry

4.3.1 Anti-Allergy Drug Market

4.3.2 Asthma/COPD Drug Market

4.3.3 Benign Prostate Hyperplasia Drug Market

4.3.4 Anti-Depressant Drug market

4.3.5 Dermatitis Drug Market

4.3.6 Diabetes Drug Market

4.3.7 Hypertension Drug Market

4.3.8 Dyslipidaemia Drug Market

4.3.9 Senile Dementia Drug Market

4.3.10 Cancer Drug Market

4.3.11 Rheumatoid Arthritis Drug Market

4.3.12 Ophthalmological Drug Market

4.3.13 Liver Disease Drug Market

4.3.14 Antibiotic Drug Market

4.3.15 Vaccine Market

5.0 Government and Regulation Environment

5.1 12th Five Year Plan

5.2 Intellectual Property for Pharmaceuticals in China

5.3 State Food and Drug Administration (SFDA)

5.4 Pharmaceutical Distribution Process in China

5.5 Multinational Company Strategy for the Essential Drug List

5.5.1 Expanded Coverage of Medical Conditions

5.5.2 A Standardized Essential Drug List

5.5.3 Increased EDL Use in Class 3 and Class 2 Hospitals

5.5.4 Increased Product Quality

5.6 How did Zocor Gain Access to the National Essential Drug List?

5.7 What are the Top Selling Agents from Multinational Companies on the Essential Drug List?

5.8 What Key Strategies Should be Investigated Prior to Essential Drug List Integration?

6.0 China – Second Largest Pharma Market 2014

6.1 China – At the Forefront of Emerging Markets

6.2 Generic Medication Market and China

6.3 Novel Product Drug Development

6.4 Drug Development Cost and Outsourcing

6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals

6.6 China’s Pharmaceutical Export Market

6.7 Spot Light - China Medical City Taizhou

7.0 Global Pharmaceutical Companies Interest in China

7.1 Abbott

7.1.1 AbbVie China

7.2 AstraZeneca China

7.3 Bayer China

7.4 Boehringer Ingelheim China

7.5 Eli Lilly China

7.6 GlaxoSmithKline China

7.7 Johnson & Johnson Medical China

7.8 Merck China

7.9 Novartis China

7.10 Novo Nordisk China

7.11 Pfizer China

7.11.1 Pfizer China R&D Centre

7.11.2 Pfizer China Products

7.11.3 Pfizer Financials

7.12 Roche China

7.13 Sanofi China

8.0 Chinese Pharmaceutical Companies

8.1 Amoytop Biotech

8.1.1 Overview

8.1.2 Active Pharmaceutical Products

8.2.1 Research and Development

8.2.2 Financial Information

8.3 Beijing Continent Pharmaceuticals

8.4 FusoGen Pharmaceuticals

8.4.1 Financial Information

8.5 Shanghai Huaguan Biochip

8.5.1 Financial Information

8.6 SiBiono GeneTech

8.6.1 Financial Information

8.7 Sinovac Biotech

8.7.1 Financial Information

8.7.2 New Products

8.7.3 Split Virion Pandemic Influenza Vaccine

8.7.4 RabEnd

8.7.5 Pipeline Portfolio

8.7.6 EV71 virus Vaccine

8.7.7 Pneumococcal Conjugate Vaccine

8.7.8 Pneumococcal Polysaccharide Vaccine

8.7.9 Varicella Vaccine

8.7.10 Measles, Mumps and Rubella Vaccines

8.7.11 Rotavirus Vaccine

9.0 Drivers, Restraints, Challenges and Opportunity Analysis

9.1 Key Drivers of the Pharmaceutical Market in China

9.2 Key Restraints of the Pharmaceutical Market in China

9.3 Challenges of the Pharmaceutical Industry in China

9.4 Opportunities Within BioPharma China

List of Tables
Table 2.1: Most Prominent Cancer Manifestations in China

Table 2.2: Top Fifty Diseases in China Today (non-cancer)

Table 2.3: Top Infectious Disease States in China Today

Table 3.1: World Trade Organisation Basic Indicators on China

Table 3.2: World Trade Organisation Trade Policy of China

Table 3.3: World Trade Organisation Merchandise Trade Statistics: China

Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China

Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China

Table 3.6: China Statistics

Table 4.1: Top Global Pharma Markets 2003-2013

Table 4.2: Major Players in China’s Anti-Allergy Drug Market

Table 4.3: Major Players in China’s Asthma Drug Market

Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market

Table 4.5: Major Players in China’s Anti-Depressant Drug Market

Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics

Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market

Table 4.8: Major Players in China’s Dermatitis Drug Market

Table 4.9: Major Players in China’s Diabetic Drug Market

Table 4.10: Major Players in China’s Hypertension Drug Market

Table 4.11: Major Players in China’s Dyslipidaemia Drug Market

Table 4.12: Major Players in China’s Senile Dementia Drug Market

Table 4.13: Major Players in China’s Cancer Drug Market

Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market

Table 4.15: Major Players in China’s Ophthalmological Drug Market

Table 4.16: Major Players in China’s Liver Disease Drug Market

Table 4.17: Major Players in China’s Antibiotic Drug Market

Table 5.1: Seven Strategic Emerging Industries of China’s 12th Five Year Plan 2011-2015

Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012

Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China

Table 5.4: Prescription Drug Sales Distribution Channels in China

Table 5.5: Extra Government Guidelines for the Chinese Essential Drug System

Table 6.1: Major Biogeneric Products in China

Table 6.2: Imported Therapeutics with Administrative Protection in China

Table 6.3: Expired Proprietary Pharmaceuticals in China

Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China

Table 6.5: Comparison of Clinical Trial Cost between China and the USA

Table 6.6: Five Functional Districts of China Medical City

Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City

Table 7.1: Top Multinational Company Performance, China

Table 7.2: Abbott Areas of Expertise

Table 7.3: Abbott Key Global Products

Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions

Table 7.5: Abbott China Anaesthesia Product Profile

Table 7.6: Abbott China Cardiovascular Product Profile

Table 7.7: Abbott China Vaccine Product Profile

Table 7.8: Abbott China Digestion Product Profile

Table 7.9: Abbott China HIV Product Profile

Table 7.10: Abbott Rheumatology HIV Product Profile

Table 7.11 Abbott China Gynaecological Product Profile

Table 7.12 Abbott China Urological Product Profile

Table 7.13 Abbott China Liver Disease Product Profile

Table 7.14 Abbott China Diagnostic Product Profile

Table 7.15: Abbott China Molecular Diagnostic Product Profile

Table 7.16: Abbott Blood Glucose Meter Product Profile

Table 7.17: Abbott Cardiovascular Product Profile

Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile

Table 7.19: Important Milestones in AstraZeneca China’s History

Table 7.20: AstraZeneca China Anaesthetic Range of Products

Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products

Table 7.22: AstraZeneca China Gastrointestinal Range of Products

Table 7.23: AstraZeneca China Infection Range of Products

Table 7.24: AstraZeneca China Neurology Range of Products

Table 7.25: AstraZeneca China Oncology Range of Products

Table 7.26: AstraZeneca China Respiratory Range of Products

Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 2014

Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 2010-2014

Table 7.29: Bayer China Important Milestones

Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China

Table 7.31: Bayer - Leading Therapeutics in China

Table 7.32: Bayer Top Selling Consumer Health Products

Table 7.33: Bayer Key Product Patent Expiration Dates China

Table 7.34: Boehringer Ingelheim Major Products in China

Table 7.35: Main Therapeutic Areas of Interest to Boehringer Ingelheim China

Table 7.36: Global Therapeutic Pipeline, Boehringer Ingelheim

Table 7.37: Major Global Boehringer Ingelheim Therapeutic Products

Table 7.38: Lilly Late Stage New Molecular Entities: Indication, Geography & Developments

Table 7.39: Lilly New Molecular Entities Approved, Under Regulatory Review & in Clinical Trials in the US, Japan and Europe

Table 7.40: Lilly Key Product by US Revenue and Patent Protection Data FY2014

Table 7.41: Lilly Key Product by Non-US Revenue and Patent Protection Data FY2014

Table 7.42: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 & Percentage Change

Table 7.43: Lilly Top Selling Global Branded Pharmaceuticals FY2014 ($ millions) Within and Outside the US Market

Table 7.44: GlaxoSmithKline Prescription Portfolio and Indications in China

Table 7.45: GlaxoSmithKline Vaccine Portfolio and Indications in China

Table 7.46: GlaxoSmithKline Over the Counter Portfolio and Indications in China

Table 7.47: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2014

Table 7.48: GlaxoSmithKline Global Vaccine Sales FY2012-2013

Table 7.49: Significant Milestones in Johnson and Johnson China History

Table 7.50: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012-2014

Table 7.51: Merck Serono Pharmaceutical Key Therapeutic Areas in China

Table 7.52: Merck Serono Fertility and Infertility Therapeutic Portfolio in China

Table 7.53: Merck Serono Therapeutic Portfolio in China

Table 7.54: Merck Pharmaceutical Hong Kong Therapeutic Portfolio

Table 7.55: Merck Main Pharmaceutical Brand Sales Figures FY2012-FY2014

Table 7.56: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013

Table 7.57: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013

Table 7.58: Range of Diabetic Products from Novo Nordisk China

Table 7.59: QUICKFACTs - Pfizer China

Table 7.60: Important Milestones – Pfizer China

Table 7.61: Pfizer Range of Infectious Disease Therapeutics for Chinese Health Care Market

Table 7.62: Pfizer Range of Mental Health Products for Chinese Health Care Market

Table 7.63: Pfizer Range of Genitourinary Products for Chinese Health Care Market

Table 7.64: Pfizer Range of Endocrine Products for Chinese Health Care Market

Table 7.65: Pfizer Range of Women’s Health Products for Chinese Health Care Market

Table 7.66: Pfizer Range of Cardiovascular Disease Products for Chinese Health Care Market

Table 7.67: Pfizer China – Range of Oncology Products for Chinese Health Care Market

Table 7.68: Pfizer Key Consumer Healthcare Global Products

Table 7.69: Pfizer Key Speciality Care Global Products

Table 7.70: Pfizer Key Oncology Global Products

Table 7.71: Pfizer Key Global Established Products

Table 7.72: Pfizer Key Innovative Products in Emerging Markets

Table 7.73: Pfizer Key Animal Health Global Products

Table 7.74: Pfizer Product Sales with Significant Impact on Revenues 2013:2014 Comparison

Table 7.75: Roche Pharmaceuticals Product List in China

Table 7.76: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2014 and Percentage Change (CER)

Table 7.77: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011-2014 and Percentage Change (CER)

Table 7.78: Seven Growth Platforms of Sanofi China

Table 7.79: Key Therapeutic Areas of Sanofi China

Table 8.1: Important Milestones in Amoytop Biotech’s Development

Table 8.2: Amoytop Biotech Main Objectives of Research and Development Division

Table 8.3: Amoytop Biotech Panel of Recombinant Protein Therapeutics in Clinical Studies

Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China

Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech

Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech

Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals

Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals

Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio

Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile

Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio

Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio

Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio

Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech

Table 8.15: Gendicine - Potential Oncology Indications for Future Approval

Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech

Table 8.17: Important Milestones in the History of Sinovac Biotech

Table 8.18: Pipeline Portfolio of Sinovac Biotech

Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012

Table 9.1: Key Drivers of the Pharmaceutical Market in China

Table 9.2: Key Restraints of the Pharmaceutical Market in China

Table 9.3: Key Challenges of the Pharmaceutical Market in China

Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020

Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China

List of Figures
Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages

Figure 3.1: China GDP Figures 2006-2015

Figure 3.2: Annual Health Expenditure in China 2006-2015

Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013

Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013

Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013

Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013

Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013

Figure 3.8: Global, US and Germany Economic Growth 2010-2013

Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017

Figure 3.10: Global, France and Italy Economic Growth 2010-2013

Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017

Figure 3.12: Global, UK and Spain Economic Growth 2010-2013

Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013

Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017

Figure 4.1: The Chinese Healthcare Industry by Sector

Figure 4.2: Global Diabetes Market, USA, Europe, Japan, RoW, 2015

Figure 4.3: Diabetes Market China 2009-2015

Figure 4.4: Global Dementia Market 2011-2017

Figure 4.5: Market Share of State-Owned, Privately-Owned and Foreign-Owned Enterprises in the Chinese Vaccine Market

Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution to 2020

Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs

Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials

Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market

Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market

Figure 5.6: Number of Drugs on Essential Drug List by Western Therapeutic and Traditional Chinese Medicine, 2009-2014

Figure 5.7: Sales of Merck’s Zocor and its Performance After Inclusion on Essential Drug List

Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth

Figure 6.2: Number of Investigational New Drug Applications in China 2003-2013

Figure 6.3: Number of New Drug Applications in China 2003-2013

Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China

Figure 6.5: Percentage of Clinical Trial Drug by Disease State

Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage

Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export

Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China

Figure 7.1: Abbott Division Sales Percentage by Diagnostics, Nutrition, Medical Devices & Established Pharmaceuticals 2014

Figure 7.2: Abbott Medical Device Segment Sales 2014 – Vascular, Diabetes and Vision

Figure 7.3: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and Emerging Markets

Figure 7.4: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015

Figure 7.5: Abbott – Business Specialization Strategy: Diversified Medical Products and Research-Based Pharmaceuticals

Figure 7.6: Abbott Diversified Medical Product Portfolio

Figure 7.7: AbbVie Global Revenue 2013-2014

Figure 7.8: AbbVie Global, International and USA Total Revenue 2014

Figure 7.9: AbbVie Global, USA & International Revenue Generated 2013-2014

Figure 7.10: AbbVie Revenue Generated by Creon, DuoDopa and Synthroid 2013-2014

Figure 7.11: AstraZeneca Sales Revenue (US$ Millions) in China, FY2010-2014

Figure 7.12: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Europe, China, Japan, Canada, FY2014

Figure 7.13: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales FY2010-2014

Figure 7.14: AstraZeneca Gastrointestinal Product (Nexium) Global Sales FY2010-2014

Figure 7.15: AstraZeneca Infection Product (Synagis) Global Sales FY2010-2014

Figure 7.16: AstraZeneca Neuroscience Product (Seroquel-IR, Seroquel-XR) Global Sales FY2010-2014

Figure 7.17: AstraZeneca Oncology Product (Zoladex) Global Sales FY2010-2014

Figure 7.18: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012

Figure 7.19: Bayer Geographical Sales China, USA, Germany FY2013-2014

Figure 7.20: Bayer Sales Distribution by Division: Healthcare, Crop Science, Material Science FY2014

Figure 7.21: Bayer Healthcare Sales Breakdown: Pharmaceuticals and Consumer Health FY2014

Figure 7.22: Boehringer Ingelheim Global Sales by Geographic Region, Europe, Americas, Asia, Australia, Africa FY2014

Figure 7.23: Boehringer Ingelheim Sales by Product Class FY2014

Figure 7.24: Boehringer Ingelheim Oncology Compounds in Development

Figure 7.25: Lilly Global Revenue FY2010-FY2014

Figure 7.26: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012-2014 (£ Billions)

Figure 7.27: GlaxoSmithKline Global Pharmaceutical Sales (£ Millions) by Therapeutic Area, FY2012-2013

Figure 7.28: GlaxoSmithKline Sales by Therapeutic Area FY2014

Figure 7.29: GlaxoSmithKline Global Vaccine Sales, FY2012-2014

Figure 7.30: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging Markets, Japan, FY2012-2014

Figure 7.31: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012-2014

Figure 7.32: Novartis International Sales (%) by Geographic Region, FY2013-FY2014

Figure 7.33: Novartis International Sales (US$ Millions) by Geographic Region, FY2012-FY2014

Figure 7.34: Novo Nordisk Total China Sales FY2009-FY2014

Figure 7.35: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China FY2010-FY2014

Figure 7.36: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China FY2010-FY2014

Figure 7.37: Business Sectors – Pfizer China

Figure 7.38: Roche Total Global Sales (CHF Millions) FY2012-FY2014

Figure 7.39: Roche Global Sales (CHF Billions) by Therapeutic Area, FY2012-FY2014

Figure 7.40: Roche Pharmaceutical Division Emerging Market Total Sales FY2011-FY2014

Figure 7.41: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, FY2012 - FY2014

Figure 7.42: Roche Pharmaceutical Division Sales in China FY2012-FY2014

Figure 7.43: Sanofi Geographic Market Share – Emerging Markets, USA and Western Europe FY2013 FY2014

Figure 7.44: Sanofi Geographic Market Share (%) –China, Russia and USA 2012

Figure 7.45: Sanofi Global Diabetes Revenue by Brand FY2014

Figure 7.46: Sanofi Global Rare Disease Revenue by Brand FY2014

Figure 7.47: Sanofi Global Multiple Sclerosis Revenue by Brand FY2014

Figure 7.48: Sanofi Global Oncology Revenue by Brand FY2014

Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression

Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service

Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012

Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012

Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012

Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012

Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012

Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • MORE

This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

The Chinese Pharmaceutical market is currently the second greatest pharma market globally, after the US and in 2014 was worth $105 billion. It is forecast to increase dramatically to $200 billion by 2020 and increase its dominance as a leading player in Asia.

This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the current economic climate and how China compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, diabetes and vaccines are elucidated and analysed.

This study reveals market figures of the overall Chinese pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in China. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the Chinese biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.

Note: Product cover images may vary from those shown
4 of 5

- Amoytop Biotech
- Active Pharmaceutical Products
- Beijing Continent Pharmaceuticals
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Abbott
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson Medical
- Merck
- Novartis
- Pfizer
- Roche

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Pfizer Inc.
  • CSL Limited
  • Novartis AG
  • Qiagen N.V.
  • Quintiles Transnational
  • Roche Diagnostics Ltd.